Johnson & Johnson (JNJ): Share Repurchases
$5.95B
Year ended 2025-12-28
$8.07B
Trailing 12 months to 2026-06-28
-0.5%
3-year compound annual growth
+13.1%
5-year compound annual growth
+1.2%
10-year compound annual growth
| Period ended | Share Repurchases | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $5.95B | +144.8% | 2026-02-11, From 2024-12-30 |
| 2024-12-29 | $2.43B | -51.9% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $5.05B | -16.3% | 2026-02-11, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $6.04B | +74.6% | 2025-02-13, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $3.46B | +7.3% | 2024-02-16, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $3.22B | -52.3% | 2023-02-16, From 2019-12-30 |
| 2019-12-29 | $6.75B | +15.0% | 2022-02-17, From 2018-12-31 |
| 2018-12-30 | $5.87B | -7.7% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $6.36B | -29.2% | 2020-02-18, From 2017-01-02 |
| 2017-01-01, Fiscal 2016 | $8.98B | +69.7% | 2019-02-20, From 2016-01-04 |
| 2016-01-03, Fiscal 2015 | $5.29B | -25.7% | 2018-02-21, From 2014-12-29 |
| 2014-12-28 | $7.12B | +101.4% | 2017-02-27, From 2013-12-30 |
| 2013-12-29 | $3.54B | -72.6% | 2016-02-24, From 2012-12-31 |
| 2012-12-30 | $12.92B | +411.6% | 2015-02-24, From 2012-01-02 |
| 2012-01-01, Fiscal 2011 | $2.52B | -9.7% | 2014-02-21, From 2011-01-03 |
| 2011-01-02, Fiscal 2010 | $2.80B | +31.3% | 2013-02-22, From 2010-01-04 |
| 2010-01-03, Fiscal 2009 | $2.13B | -68.0% | 2012-02-23, From 2008-12-29 |
| 2008-12-28 | $6.65B | +18.6% | 2011-02-25, From 2007-12-31 |
| 2007-12-30 | $5.61B | n/a | 2010-03-01, From 2007-01-01 |
Share Repurchases at similar companies
| Company | Year ended | Share Repurchases | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $5.95B | +144.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $4.11B | +64.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $5.08B | +289.3% |
| Pfizer Inc (PFE) | 2024-12-31 | $0 | n/a |
| AbbVie Inc. (ABBV) | 2025-12-31 | $980.00M | -42.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $0 | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $893.00M | -31.0% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.44B | +32.1% |
| Viatris Inc (VTRS) | 2025-12-31 | $500.50M | +100.2% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗